Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ASTRAZENECA LIMITED,Trastuzumab deruxtecan,"breast cancer, unresectable or metastatic, HER2 low (IHC 1+ or IHC 2+ or ISH negative)",Trastuzumab deruxtecan (Enhertu),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
